I think RAC are focusing their Reformulation on improving the delivery system, and possibly even a pill form.
Any Collaboration with OTHER Drug reformulations, would likely be done by those specific drug companies, rather than RAC.
And this would likely only be under a Partnership/Licensing deal
Ann: Expanded Heart Protection Discovery for Zantrene, page-53
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.01 |
Change
0.260(14.9%) |
Mkt cap ! $350.7M | |||
| Open | High | Low | Value | Volume |
| $1.87 | $2.08 | $1.86 | $1.269M | 645.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 505 | $1.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.02 | 4543 | 2 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.02 |
Change
0.260 ( 16.2 %) |
||||
| Open | High | Low | Volume | ||
| $1.86 | $2.08 | $1.86 | 50369 | ||
| Last updated 15.59pm 18/06/2024 ? | |||||
| RAC (ASX) Chart |